| Literature DB >> 29518973 |
Meng-Lun Chang1, Hui-Ching Mei2, I-Chih Kuo3, George Hsiao4, Yueh-Hsiung Kuo5,6, Ching-Kuo Lee7,8,9.
Abstract
Chamaecyparis formosensis is Taiwan's most representative tree, and has high economic value. To date, only a few active chemical constituents have been reported for C. formosensis. In this study, 37 secondary metabolites, including three new compounds (1-3), were extracted from the leaves of C. formosensis. The compounds isolated from the ethyl acetate layer were used at different concentrations to treat HT-1080 human fibrosarcoma cells and to evaluate their effects on matrix metalloprotease 2 (MMP-2) and 9 (MMP-9) expression. Based on extensive analysis of data from high-resolution mass spectrometry (HR-MS) as well as nuclear magnetic resonance (NMR), infrared (IR), and ultraviolet (UV) spectroscopy, the new compounds were identified as 11,12-dihydroxyisodaucenoic acid (1), 12-hydroxyisodaucenoic acid (2), and 1-oxo-2α,3β-dihydroxytotarol (3). Known compounds 4-37 were identified by comparing their spectroscopic data with data reported in the literature. Biological activity tests by gelatin zymographic analysis revealed that seven compounds, including new compound 2, have no cytotoxic effect on HT-1080 cells and were found to increase MMP-2 or MMP-9 expression by 1.25- to 1.59-fold at lower concentrations of 10-50 µM. These naturally derived regulatory compounds could potentially serve as a novel pharmaceutical basis for medical purposes.Entities:
Keywords: Chamaecyparis formosensis; Cupressaceae; HT-1080; MMP-2; MMP-9; terpenoids
Mesh:
Substances:
Year: 2018 PMID: 29518973 PMCID: PMC6017238 DOI: 10.3390/molecules23030604
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of compounds 1–3.
1H- and 13C-NMR spectral data of 1 and 2 (acetone-d6, 500 MHz).
| Position | 1 | 2 | ||
|---|---|---|---|---|
| δH | δC | δH | δC | |
| 1 | 1.99 (1H, m) | 58.0 | 1.89 (1H, m) | 57.2 |
| 2 | 1.48 (1H, m) | 24.2 | 1.25 (1H, m) | 24.0 |
| 3 | 1.80 (1H, m) | 30.9 | 3.03 (1H, m) | 28.4 |
| 4 | 136.4 | 134.5 | ||
| 5 | 7.10 | 142.2 | 7.20 | 144.8 |
| 6 | 2.40 (1H, m) | 43.3 | 2.45 (1H, dd, | 43.0 |
| 7 | 42.7 | 42.9 | ||
| 8 | 1.38 (1H, m) | 42.4 | 1.58 (1H, br dd, | 42.5 |
| 9 | 1.65 (1H, m) | 27.7 | 1.70 (2H, m) | 30.1 |
| 10 | 2.59 (1H, m) | 48.6 | 2.91 (1H, m) | 45.6 |
| 11 | 75.9 | 151.7 | ||
| 12 | 3.28 (1H, d, | 70.9 | 4.06 (1H, d, | 67.7 |
| 13 | 1.10 (3H, s) | 22.0 | 4.93 (1H, br s), 5.16 (1H, br s) | 111.4 |
| 14 | 169.6 | 172.8 | ||
| 15 | 0.80 (3H, s) | 19.7 | 0.81 (3H, s, CH3) | 19.9 |
Figure 2(a) Selected HMBC and 1H–1H COSY spectra of compound 1; (b) selected NOESY spectrum of compound 1.
Compounds that modulate matrix metalloprotease 2 (MMP-2) and MMP-9 expression to various degrees.
| Compound | MMP-2 | MMP-9 |
|---|---|---|
| PMA | 2.5 * (Pro MMP-9 **, 1 μM ***) | |
| EGCG | 0.2–0.4 (Pro MMP-2, 100 μM) | |
| 13-Hydroxyisodaucenoic acid ( | 1.26 (50 µM) | |
| Nortrachelogenin ( | 1.30 (50 µM) | 1.54 (10 µM) |
| 8′β-hydroxynortrachelogenin ( | 1.23 (50 µM) | |
| Epicatechin ( | 1.31 (50 µM) | |
| Catechin ( | 1.29 (50 µM) | |
| 4′′′- | 1.42 (Pro MMP-9 ***, 10 µM) | |
| 4′′′,7-dimethoxyametoflavone ( | 1.18 (Pro-MMP-9, 50 µM) |
* Number of folds by which MMP-2 expression was elevated compared to the control group. ** Increased form of MMP expression. ***Concentrations of compounds used to treat HT-1080 cells.
1H- and 13C- NMR spectral data of 3 (CDCl3, 500 MHz).
| Position | δH (mult., | δC |
|---|---|---|
| 1 | 210.4 | |
| 2 | 4.70 (1H, dd, | 75.4 |
| 3 | 3.05 (1H, d, | 85.5 |
| 4 | 38.6 | |
| 5 | 1.45 (1H, dd, | 49.8 |
| 6 | 1.55 (1H, m) | 18.7 |
| 2.02 (1H, m) | ||
| 7 | 2.67 (1H, m) | 29.9 |
| 2.95 (1H, m) | ||
| 8 | 132.5 | |
| 9 | 131.3 | |
| 10 | 53.5 | |
| 11 | 6.98 (1H, d, | 128.9 |
| 12 | 6.57 (1H, d, | 114.4 |
| 13 | 153.1 | |
| 14 | 132.5 | |
| 15 | 3.20 (1H, sept) | 29.6 |
| 16 | 1.30 (3H, d, | 20.5 |
| 17 | 1.31 (3H, d, | 20.4 |
| 18 | 1.14 (3H, s) | 29.0 |
| 19 | 1.15 (3H, s) | 17.0 |
| 20 | 1.61 (3H, s) | 25.3 |